Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare
Diabetic Macular Edema (DME) Filing Possible In 2021
Executive Summary
New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.
You may also be interested in...
Novartis Big Earners Beat Q1 Forecasts
Cosentyx defied the odds again by growing strongly despite US formulary changes, COVID-19 and fierce competition, while the jump in Entresto sales helped soften the drug's failure in a closely watched myocardial infarction study.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit
The company has pledged to continue developing its Duchenne in vivo gene editing therapy without Lilly, but will remain focused on its lead program in hepatitis B.